Center for Surgery and Public Health, Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Division of Surgery and Interventional Science, University College London, London, United Kingdom; Department of Urology, University College London Hospitals, London, United Kingdom.
Center for Surgery and Public Health, Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
Clin Genitourin Cancer. 2019 Oct;17(5):e1060-e1068. doi: 10.1016/j.clgc.2019.06.008. Epub 2019 Jun 19.
We evaluated patient, hospital, and cancer-specific factors associated with positive surgical margin (PSM) variability after radical prostatectomy in pT2 prostate cancer in the United States.
A total of 45,426 men from 1152 hospitals with pT2 prostate cancer and known margin status after radical prostatectomy were identified using the National Cancer Database (2010-2015). Data on patient, cancer, hospital factors, and surgical approach were extracted. A mixed effects logistic regression model was computed to examine factors associated with PSM and partial R values to assess the relative contributions of patient, cancer, and hospital variables to PSM status.
Median PSM rate of 8.5% (interquartile range, 5.2%-13.0%). Robotic (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.83-0.99) and laparoscopic (OR, 0.74; 95% CI, 0.64-0.90) surgical approach, academic institution (OR, 0.87; 95% CI, 0.76-1.00) and high hospital surgical volume (>297 cases [OR], 0.83; 95% CI, 0.70-0.99) were independently associated with a lower PSM. Black men (OR, 1.13; 95% CI, 1.01-1.26) and adverse cancer-specific features (prostate-specific antigen [PSA], 10-20; PSA >20; cT3 stage; Gleason 7, 8, 9-10; all P > .01) were independently associated with a higher PSM. Patient-specific, hospital-specific, and cancer-specific factors had a contribution of 2.3%, 3.9%, and 15.2%, respectively, to the variation in PSM. Facility had a contribution of 23.7% to the variation in PSM.
Cancer-specific factors account for 15.2% of PSM variation with the remaining 84.8% of PSM variation due to patient, hospital, and other factors not accounted within the model. Noncancer-specific factors represent addressable factors that are important for policy-makers in efforts to improve patient outcome.
我们评估了美国 pT2 前列腺癌根治性前列腺切除术后与阳性切缘(PSM)变异性相关的患者、医院和癌症特异性因素。
使用国家癌症数据库(2010-2015 年),共确定了 45426 名来自 1152 家医院的 pT2 前列腺癌患者,这些患者在根治性前列腺切除术后已知有切缘状态。提取了患者、癌症、医院因素和手术方法的数据。使用混合效应逻辑回归模型计算了与 PSM 相关的因素,并计算了部分 R 值以评估患者、癌症和医院变量对 PSM 状态的相对贡献。
PSM 率的中位数为 8.5%(四分位距,5.2%-13.0%)。机器人(优势比[OR],0.90;95%置信区间[CI],0.83-0.99)和腹腔镜(OR,0.74;95%CI,0.64-0.90)手术方法、学术机构(OR,0.87;95%CI,0.76-1.00)和高医院手术量(>297 例[OR],0.83;95%CI,0.70-0.99)与较低的 PSM 独立相关。黑人男性(OR,1.13;95%CI,1.01-1.26)和不良癌症特异性特征(前列腺特异性抗原[PSA],10-20;PSA>20;cT3 期;Gleason 7、8、9-10;均 P>.01)与较高的 PSM 独立相关。患者特异性、医院特异性和癌症特异性因素对 PSM 变异性的贡献分别为 2.3%、3.9%和 15.2%。机构对 PSM 变异性的贡献为 23.7%。
癌症特异性因素占 PSM 变异性的 15.2%,其余 84.8%的 PSM 变异性归因于模型中未考虑的患者、医院和其他因素。非癌症特异性因素是政策制定者为改善患者预后而需要解决的重要因素。